Payment overview · 2025
General Payments
$951.72
39 reported records · 12 companies
Healthcare provider profile · identity verified
Michele C Marler, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GREAT FALLS, MT · NPI 1396736047
Verified facts
What the public records show
CMS Open Payments records show Michele C Marler, M.D. received $951.72 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $287.62 | 30.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $222.88 | 23.4% | 13 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $96.42 | 10.1% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $67.26 | 7.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.23 | 6.5% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $49.19 | 5.2% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $45.79 | 4.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.71 | 4.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.93 | 3.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.35 | 1.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.25 | 1.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.09 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $951.72 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $287.62 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $159.09 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $117.91 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $117.91 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $104.97 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $96.42 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $67.26 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $62.23 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $62.23 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $49.19 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $45.79 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.71 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $37.71 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.93 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.93 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
91 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
149 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 522 | 87 |
| Atorvastatin Calcium | Atorvastatin Calcium | 508 | 114 |
| Pantoprazole Sodium | Pantoprazole Sodium | 409 | 88 |
| Gabapentin | Gabapentin | 408 | 62 |
| Lisinopril | Lisinopril | 382 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 356 | 85 |
| Metformin Hcl | Metformin Hcl | 299 | 51 |
| Losartan Potassium | Losartan Potassium | 274 | 66 |
| Famotidine | Famotidine | 261 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 258 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 238 | 42 |
| Omeprazole | Omeprazole | 217 | 47 |
| Simvastatin | Simvastatin | 207 | 40 |
| Potassium Chloride | Potassium Chloride | 202 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 198 | 24 |
| Trazodone Hcl | Trazodone Hcl | 189 | 33 |
| Meloxicam | Meloxicam | 172 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 172 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 166 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 163 | 50 |
| Montelukast Sodium | Montelukast Sodium | 162 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 161 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 55 |
| Ozempic | Semaglutide | 149 | 29 |
| Donepezil Hcl | Donepezil Hcl | 145 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 141 | 34 |
| Celecoxib | Celecoxib | 138 | 34 |
| Furosemide | Furosemide | 137 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 132 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 117 | 22 |
| Eliquis | Apixaban | 116 | 19 |
| Januvia | Sitagliptin Phosphate | 113 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 113 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 110 | 25 |
| Alendronate Sodium | Alendronate Sodium | 109 | 28 |
| Metformin Hcl Er | Metformin Hcl | 109 | 22 |
| Buspirone Hcl | Buspirone Hcl | 107 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 26 |
| Pregabalin | Pregabalin | 97 | 23 |
| Sertraline Hcl | Sertraline Hcl | 95 | 15 |
| Bupropion Xl | Bupropion Hcl | 91 | 24 |
| Farxiga | Dapagliflozin Propanediol | 91 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 24 |
| Carvedilol | Carvedilol | 86 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 80 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 78 | 23 |
| Ibuprofen | Ibuprofen | 78 | 17 |
| Aripiprazole | Aripiprazole | 74 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 72 | 22 |
| Spironolactone | Spironolactone | 72 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 13 |
| Xarelto | Rivaroxaban | 68 | 14 |
| Tramadol Hcl | Tramadol Hcl | 65 | 17 |
| Memantine Hcl | Memantine Hcl | 63 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 11 |
| Mirtazapine | Mirtazapine | 59 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 17 |
| Propranolol Hcl | Propranolol Hcl | 58 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 22 |
| Alprazolam | Alprazolam | 52 | suppressed |
| Jardiance | Empagliflozin | 52 | suppressed |
| Misoprostol | Misoprostol | 52 | suppressed |
| Fenofibrate | Fenofibrate | 51 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 49 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 15 |
| Allopurinol | Allopurinol | 46 | 14 |
| Atenolol | Atenolol | 46 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 46 | suppressed |
| Lorazepam | Lorazepam | 46 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | suppressed |
| Ondansetron Odt | Ondansetron | 44 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 44 | suppressed |
| Ezetimibe | Ezetimibe | 43 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Baclofen | Baclofen | 41 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 37 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 36 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 35 | 15 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Fluconazole | Fluconazole | 32 | 17 |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Ketoconazole | Ketoconazole | 31 | suppressed |
| Nabumetone | Nabumetone | 31 | suppressed |
| Olanzapine | Olanzapine | 31 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 30 | suppressed |
| Prednisone | Prednisone | 29 | 20 |
| Acyclovir | Acyclovir | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Methimazole | Methimazole | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Novolog | Insulin Aspart | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Mitigare | Colchicine | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 11 |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Enbrel Sureclick | Etanercept | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $951.72 · 39 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, GARDASIL 9, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VAXELIS, VAXNEUVANCE, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error